Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemotherapy and Risk-Stratified Treatment for HPV+ Oropharyngeal Cancer
NCT04572100Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of carboplatin and paclitaxel in oropharyngeal squamous cell carcinoma (OPSCC) (4 arms), sponsored by University of Chicago. Primary endpoints: Feasibility of collection of serial HPV-DNA blood samples in patients undergoing treatment for Oropharyngeal Squamous Cell Carcinoma at 16 weeks and Relationship Between HPV-DNA Found in Participant's Blood and Participant Response to Chemotherapy at 16 weeks. Started Oct 2020; status: completed.
02
Drugs
carboplatinpaclitaxel
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT04572100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572100.